Artificial intelligence (AI)-based blood and cancer diagnostic platform company Noul has unveiled a cervical cell analysis product, miLab Cartridge CER, designed to automatically stain and analyse cervical cells.
The new product stains cervico-viginal samples smeared manually or by liquid-based cytology (LBC) using the Papanicolaou staining combined with Noul’s solid-based staining technology, Next Generation Staining & Immunostaining.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Noul’s new AI-based diagnostic platform, when used with miLab, will provide staining, imaging and cell analysis results. These results are expected to help in the decision-making process for the users.
Using cervical cytology as a screening method, miLab Cartridge CER can detect the detailed stages of cervical pre-cancer/cancer.
The product also helps reduce the total test time and allows users to review the overall area and identify the most diagnostically relevant cells.
Noul CEO David Lim said: “Through the launch of cervical cell analysis products, we have made a real step forward in the cancer diagnostic business. The miLab Cartridge CER is compatible with both PAP smear and LBC methods and it enables efficient and accurate cervical cell review with full automatic staining and analysis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We want to contribute to the early diagnosis of cervical cancer, the fourth largest cancer in the world for women.”
Noul introduced miLab Cartridge CER at the International Federation of Gynecology and Obstetrics 2023, taking place from 9-12 October in Paris, France.
In August 2022, Noul secured a CE mark for miLab Cartridge CER. The company’s miLab platform received the CE-IVDR mark in February this year.
